FBIO FBIOP - Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B FinancingProcee
FBIO FBIOP - Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B FinancingProceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety and efficacy for the treatment of gout
Story updates
12:03:13 PM UTC
SquawkNews
FBIO Fortress Biotech and subsidiary urica Therapeutics announce crystalys therapeutics’ $130M series B financing
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.